270 related articles for article (PubMed ID: 7749764)
1. Randomized double-blind crossover ondansetron-dexamethasone versus ondansetron-placebo study for the treatment of chemotherapy-induced nausea and vomiting in pediatric patients with malignancies.
Alvarez O; Freeman A; Bedros A; Call SK; Volsch J; Kalbermatter O; Halverson J; Convy L; Cook L; Mick K
J Pediatr Hematol Oncol; 1995 May; 17(2):145-50. PubMed ID: 7749764
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide.
Tienchaiananda P; Nipondhkit W; Maneenil K; Sa-Nguansai S; Payapwattanawong S; Laohavinij S; Maneechavakajorn J
Ann Palliat Med; 2019 Sep; 8(4):372-380. PubMed ID: 31500422
[TBL] [Abstract][Full Text] [Related]
3. Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy.
Arpornwirat W; Albert I; Hansen VL; Levin J; Bandekar RR; Grunberg SM
Cancer; 2009 Dec; 115(24):5807-16. PubMed ID: 19834961
[TBL] [Abstract][Full Text] [Related]
4. Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone.
Lindley C; Goodin S; McCune J; Kane M; Amamoo MA; Shord S; Pham T; Yowell S; Laliberte K; Schell M; Bernard S; Socinski MA
Am J Clin Oncol; 2005 Jun; 28(3):270-6. PubMed ID: 15923800
[TBL] [Abstract][Full Text] [Related]
5. Ondansetron versus ondansetron, dexamethasone, and chlorpromazine in the prevention of nausea and vomiting associated with multiple-day cisplatin chemotherapy.
Fox SM; Einhorn LH; Cox E; Powell N; Abdy A
J Clin Oncol; 1993 Dec; 11(12):2391-5. PubMed ID: 8246028
[TBL] [Abstract][Full Text] [Related]
6. A randomised, double-blind, parallel-group study to compare the efficacy and safety of ondansetron (GR38032F) plus dexamethasone with metoclopramide plus dexamethasone in the prophylaxis of nausea and emesis induced by carboplatin chemotherapy.
du Bois A; McKenna CJ; Andersson H; Lahousen M; Kitchener H; Pinter T; Capstick V; Wilkinson JR
Oncology; 1997; 54(1):7-14. PubMed ID: 8978585
[TBL] [Abstract][Full Text] [Related]
7. Prevention of nausea and vomiting (N&V) in cancer patients receiving high-dose cisplatin. Assessment of the potential antiemetic activity of transdermal fentanyl (TTS-F) compared to standard antiemetic treatment in acute and delayed N&V: first clinical report.
Mantovani G; Curreli L; Macciò A; Massa E; Massa D; Mulas C; Succu G; Contu P
Anticancer Res; 1999; 19(4C):3495-502. PubMed ID: 10629642
[TBL] [Abstract][Full Text] [Related]
8. A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group.
Olver I; Paska W; Depierre A; Seitz JF; Stewart DJ; Goedhals L; McQuade B; McRae J; Wilkinson JR
Ann Oncol; 1996 Nov; 7(9):945-52. PubMed ID: 9006746
[TBL] [Abstract][Full Text] [Related]
9. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone.
Roila F; Tonato M; Cognetti F; Cortesi E; Favalli G; Marangolo M; Amadori D; Bella MA; Gramazio V; Donati D
J Clin Oncol; 1991 Apr; 9(4):675-8. PubMed ID: 1829757
[TBL] [Abstract][Full Text] [Related]
10. Implementation of institutional antiemetic guidelines for low emetic risk chemotherapy with docetaxel: a clinical and cost evaluation.
Hayashi T; Ikesue H; Esaki T; Fukazawa M; Abe M; Ohno S; Tomizawa T; Oishi R
Support Care Cancer; 2012 Aug; 20(8):1805-10. PubMed ID: 21947491
[TBL] [Abstract][Full Text] [Related]
11. A randomized double-blind trial of ondansetron alone versus in combination with dexamethasone versus in combination with dexamethasone and lorazepam in the prevention of emesis due to cisplatin-based chemotherapy.
Ahn MJ; Lee JS; Lee KH; Suh C; Choi SS; Kim SH
Am J Clin Oncol; 1994 Apr; 17(2):150-6. PubMed ID: 8141107
[TBL] [Abstract][Full Text] [Related]
12. Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naive and previously treated patients. Swiss Group for Clinical Cancer Research (SAKK).
Joss RA; Bacchi M; Buser K; Kirchner V; Neuenschwander H; Orth B; Aapro MS; Thürlimann B
Ann Oncol; 1994 Mar; 5(3):253-8. PubMed ID: 8186174
[TBL] [Abstract][Full Text] [Related]
13. Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group.
Kaizer L; Warr D; Hoskins P; Latreille J; Lofters W; Yau J; Palmer M; Zee B; Levy M; Pater J
J Clin Oncol; 1994 May; 12(5):1050-7. PubMed ID: 8164029
[TBL] [Abstract][Full Text] [Related]
14. Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy.
Smith DB; Newlands ES; Rustin GJ; Begent RH; Howells N; McQuade B; Bagshawe KD
Lancet; 1991 Aug; 338(8765):487-90. PubMed ID: 1714532
[TBL] [Abstract][Full Text] [Related]
15. Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting.
Roila F; Rolski J; Ramlau R; Dediu M; Russo MW; Bandekar RR; Grunberg SM
Ann Oncol; 2009 Nov; 20(11):1867-73. PubMed ID: 19541792
[TBL] [Abstract][Full Text] [Related]
16. Randomized, double-blind comparison of ondansetron versus ondansetron plus metopimazine as antiemetic prophylaxis during platinum-based chemotherapy in patients with cancer.
Herrstedt J; Sigsgaard T; Handberg J; Schousboe BM; Hansen M; Dombernowsky P
J Clin Oncol; 1997 Apr; 15(4):1690-6. PubMed ID: 9193370
[TBL] [Abstract][Full Text] [Related]
17. Survey ranking of emetogenic control in children receiving chemotherapy.
Small BE; Holdsworth MT; Raisch DW; Winter SS
J Pediatr Hematol Oncol; 2000; 22(2):125-32. PubMed ID: 10779025
[TBL] [Abstract][Full Text] [Related]
18. [Value of the combination of oral ondansetron with methylprednisolone as soon as the first cure in mild emetogenic chemotherapy. Groupe français d'étude de l'ondansétron].
Coiffier B; Khayat D; Misset JL; Votan B
Bull Cancer; 1997 Aug; 84(8):781-7. PubMed ID: 9339181
[TBL] [Abstract][Full Text] [Related]
19. Antiemetic efficacy of ondansetron and metoclopramide, both combined with corticosteroid, in malignant lymphoma patients receiving non-cisplatin chemotherapy.
Jørgensen M; Victor MA
Acta Oncol; 1996; 35(2):159-63. PubMed ID: 8639310
[TBL] [Abstract][Full Text] [Related]
20. Dexamethasone plus ondansetron versus dexamethasone plus alizapride in the prevention of emesis induced by cisplatin-containing chemotherapies for urological cancers.
Nicolai N; Mangiarotti B; Salvioni R; Piva L; Faustini M; Pizzocaro G
Eur Urol; 1993; 23(4):450-6. PubMed ID: 8335048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
